35 results on '"Sundar R"'
Search Results
2. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
3. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
4. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer.
5. 229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies
6. 1418P Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial
7. 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
8. 1835P Clinical outcome and prognostic factors for Asian patients in phase I clinical trials
9. P-19 A multicentred phase II clinical trial on yttrium 90-resin microspheres followed by gemcitabine-cisplatin for treatment of locally advanced intra-hepatic cholangiocarcinoma
10. 82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
11. 719TiP A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
12. 593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts)
13. 1565P ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
14. 1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis
15. 1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases
16. 2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
17. 40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies
18. P-159 First-in-human phase 1 dose-escalating study protocol of pressurized intraperitoneal aerosol chemotherapy with paclitaxel in peritoneal carcinomatosis (PIPAC2 study)
19. Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)
20. Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital
21. Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy
22. 463P - Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)
23. RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity
24. TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
25. Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit
26. 127O Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results
27. 1194P - Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy
28. 398P - Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital
29. 404P - Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit
30. 383P - RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity
31. 362PD - TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
32. 160P Peritoneal niche evolution and micro-environmental remodeling in gastric cancer peritoneal metastasis.
33. 539P An advanced practice nurse-led teleconsultation service for rectal cancer patients undergoing concurrent chemoradiation.
34. 159P Spatial organization of B cells in the prediction and prognosis of gastric cancer.
35. 98P Real-world evidence on total neoadjuvant therapy (TNT) vs neoadjuvant concurrent chemoradiation (NA CCRT) for locally advanced rectal cancer (LARC) from a Tertiary Asian Cancer Centre.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.